A tech crowd was polled on buying Anthropic shares at a $3 trillion valuation. Only 3 hands went up.

Anthropic’s expected IPO is shaping up as a major test of whether public investors will support AI-era private valuations; at a San Francisco event, only three attendees said they would buy at a $3 trillion valuation. IPO dollars raised are already among the highest on record, driven by SpaceX’s debut, but the market remains thin, and Oura recently withdrew its planned offering amid choppy conditions. Nasdaq’s listings chief said capital remains available, but investors now demand growth with cash efficiency and discipline; biotech has recorded 22 IPOs this year.

Analysis

The signal is a bifurcated IPO market, not proof that public capital has run out: a mega-offering can absorb attention and underwriting capacity while leaving smaller issuers without a reliable clearing price. If Anthropic or OpenAI prices aggressively, weak aftermarket performance would reset private-market marks, raise the equity hurdle for late-stage software and consumer companies, and pressure venture portfolios that depend on exits. A disciplined offer with positive aftermarket trading could instead reopen the queue and improve liquidity for venture investors. SpaceX’s reported debut is not evidence that demand generalizes beyond a scarce, highly visible issuer.

Near term (days to weeks), treat event chatter and informal investor polling as weak evidence; offering terms and order-book quality matter more. Over 1–3 months, watch the frontier-lab filing, valuation, dilution, use of proceeds, and first-week trading for the market-clearing signal. Over 6–18 months, sustained cash-efficiency scrutiny could divert issuance toward businesses with nearer-term measurable economics; biotech activity may be less exposed to the same AI attention bottleneck, though it has distinct risks. Oura’s withdrawn deal is a caution for prospective issuers, not evidence of a consolidated-company earnings change.

Contrarian point: the headline IPO-dollar tally can mask narrow breadth. Avoid extrapolating one blockbuster to the wider growth universe; equally, a conservative AI IPO that trades well could release rather than permanently crowd out demand. The article provides no filing economics or independent demand data, so no directional position in Oura or SpaceX is supported on this evidence alone.

Key Decisions for Investors

• Do not chase IPO-exposure baskets solely on headline proceeds. Keep broad new-issue exposure tactical until breadth and aftermarket performance confirm demand beyond SpaceX.
• Set an event alert for Anthropic and OpenAI filing terms: valuation, dilution, cash use, and disclosed unit economics. A high-priced deal followed by weak trading would favor reducing exposure to richly valued, cash-burning software and late-stage private-market proxies; a disciplined deal with durable trading would invalidate that cautious stance.
• For Oura, treat the withdrawn IPO as a signal to verify any revised timetable and pricing rather than as a public-equity short thesis; the article supplies no listed Oura trading instrument or evidence of a change in operating results.
• Monitor whether consumer and software issuance resumes after the frontier-lab offerings and compare it with biotech issuance breadth. Broad postponements, repeated price cuts, or deteriorating first-week returns would confirm a narrow IPO window; successful follow-on offerings would weaken the crowding thesis.